All our products are based on the following technologies:
Immune Monitoring in Cancer
Detect Cancer-Specific T-cell Immunity
Immune monitoring of T cells provides insight about existing or induced immunity within patients receiving treatment for their cancer. Identifying cancer-specific T cells can be an important tool to understand how different treatments impact the immune response and help define properties of the patient's immune response that correlates with successful or unsuccessful therapy.
Dextramer® reagents can detect, quantify, or isolate cancer-specific T cells subsets in peripheral blood or tumor biopsies, using flow cytometry.
Learn more about cancer-specific Dextramer collections:
The Melanoma Dextramer® Collection 1
Melanoma is a malignant neoplasm of melanocytes arising de novo or from a benign nevus. Tumor-reactive T cells specific for a range of melanoma-associated antigens have been isolated from melanoma patients. Important melanoma-antigens include melanocyte lineage proteins like Tyrosinase, gp100, MART-1, and Cancer-Testis antigens like the MAGE proteins and NY-ESO-1. These are all potentially suitable targets for tumor vaccines because of their high immunogenicity in vivo and their restricted distribution in normal tissue. Immune monitoring and quantification of antigen-specific CD8+ T cells that can recognize these antigens can provide information about melanoma-specific immunity.
The collection contains melanoma-specific MHC I Dextramer reagents that display epitopes from six different melanoma-associated antigens. Each Dextramer specificity is provided as a PE- and APC conjugate which enables double staining of each cell sample to better resolve Dextramer positive from negative subsets in the flow cytometry analysis. The collection also includes a negative control Dextramer.
Cat. no RX01
| Melanoma-specific Dextramer® MHC Allele/Peptide/Fluorophore |
Antigen | Tests* |
| HLA-A*0201 / ELAGIGILTV-PE | MART-1 | 25 tests |
| HLA-A*0201 / ELAGIGILTV-APC | MART-1 | 25 tests |
| HLA-A*0201 / SLLMWITQV-PE | NY-ESO-1 | 25 tests |
| HLA-A*0201 / SLLMWITQV-APC | NY-ESO-1 | 25 tests |
| HLA-A*0201 / KVAELVHFL-PE | MAGE-A3 | 25 tests |
| HLA-A*0201 / KVAELVHFL-APC | MAGE-A3 | 25 tests |
| HLA-A*0201 / YMDGTMSQV-PE | Tyrosinase | 25 tests |
| HLA-A*0201 / YMDGTMSQV-APC | Tyrosinase | 25 tests |
| HLA-A*0201 / IMDQVPFSV-PE | gp100 | 25 tests |
| HLA-A*0201 / IMDQVPFSV-APC | gp100 | 25 tests |
| HLA-A*0201 / KVLEYVIKV-PE | MAGE-A1 | 25 tests |
| HLA-A*0201 / KVLEYVIKV-APC | MAGE-A1 | 25 tests |
| HLA-A*0201 / Negative Control-PE | - | 25 tests |
| HLA-A*0201 / Negative Control-APC | - | 25 tests |
* One test is defined as 10 µl MHC Dextramer reagent sufficient to stain up to 1-3 x 10^6 lymphoid cells or 1-3 x 10^5 clonal antigen-specific T cells.
The Melanoma Dextramer® Collection 1 is for research use only.
The Cancer-Testis Antigens Dextramer® Collection 1
Cancer-Testis antigens (CTA) constitute a family of proteins that exhibit a remarkably restricted expression in gametogenic tissue and are consequently not exposed to the systemic immune system. This means that no immunological tolerance is established. CTA is over-expressed, and cellular immune responses have been reported in patients with a variety of tumors.
Immune monitoring and quantification of antigen-specific CD8+ T cells that can recognize these antigens can provide information about CTA-specific immunity.
The collection contains CTA-specific MHC I Dextramer displaying epitopes from three different Cancer-Testis antigens. Each Dextramer-specificity is provided as a PE- and APC conjugate which enables double staining of each cell sample to better resolve Dextramer positive from negative subsets in the flow cytometry analysis. The collection also includes a negative control Dextramer.
Cat. No. RX02
| CTA-specific Dextramer® MHC Allele/Peptide/Fluorophore |
Antigen | Tests* |
| HLA-A*0201 / SLLMWITQV-PE | NY-ESO-1 | 25 tests |
| HLA-A*0201 / SLLMWITQV-APC | NY-ESO-1 | 25 tests |
| HLA-A*0201 / KVAELVHFL-PE | MAGE-A3 | 25 tests |
| HLA-A*0201 / KVAELVHFL-APC | MAGE-A3 | 25 tests |
| HLA-A*0201 / KVLEYVIKV-PE | MAGE-A1 | 25 tests |
| HLA-A*0201 / KVLEYVIKV-APC | MAGE-A1 | 25 tests |
| HLA-A*0201 / Negative Control-PE | - | 25 tests |
| HLA-A*0201 / Negative Control-APC | - | 25 tests |
* One test is defined as 10 µl MHC Dextramer reagent sufficient to stain up to 1-3 x 10^6 lymphoid cells or 1-3 x 10^5 clonal antigen-specific T cells.
The Cancer-Testis Antigens Dextramer® Collection 1 is for research use only.
How to Order the Cancer-Specific Dextramer® Collections
Send an e-mail to ordering@immudex.com specifying cat. no.
| Product | Status | Size | Cat. No. | Price (EUR) | Price (USD) |
| Melanoma Dextramer Collection 1 | RUO | 12 x 25 tests | RX01 | 6.199 | 6,929 |
| Cancer-Testis Antigens Dextramer Collection 1 | RUO | 8 x 25 tests | RX02 | 4.099 | 4,599 |
Related Products
The Dextramer® reagents included in the two collections are available as single reagents.
Additional cancer-specific Dextramer reagents not included in the two collections are available:
- Suggested Dextramer reagents can be found here by searching for " Melanoma" or "Cancer" in the category field
- Customer-defined Dextramer reagents with your choice of MHC-peptide combination are easily made with MHC alleles from our catalog and with peptides that form stable complexes with the MHC molecule
Contact Us
Ordering
Email: ordering@immudex.com
Ordering: +45 29 13 42 24
Main: +45 31 10 91 91
Fax: +45 77 31 15 09
CVR/VAT no. 31348854
Technical Support
Email: customer@immudex.com